NYU Langone Seminar in Advanced Rheumatology

Thursday - Saturday, March 17-19, 2016 

NYU Langone Medical Center
550 First Avenue (31st Street)
Alumni Hall, Farkas Auditorium
New York, NY 10016

Course Brochure

Register Online*

Register Via Fax*

*After 12 pm on March 15, 2016, only onsite registration is available, provided the course has not reached capacity. Onsite registrants will incur an additional $20 fee. Registration is non-transferable.

Course Directors

Steven B. Abramson, MD

Jill P. Buyon, MD

Bruce N. Cronstein, MD

Michael H. Pillinger, MD


Please click here for more information on the Musculoskeletal Ultrasound for Rheumatologists: Beginner and Intermediate Levels course.


Course Fees

Full Fee: $575
Reduced Fee*: $375
NYU Langone Rheumatology Department: $150
NYU Langone Residents and Fellows: Waived
Lunchtime Workshops: $25

*Reduced fee applies to NYU School of Medicine alumni, former residents and fellows; physicians-in-training with letter of certification from the Chief of Service; physicians employed by the Department of Veterans Affairs Medical Center; and full-time active military personnel; retired physicians; and all other non-physician healthcare professionals.

Target Audience

This course is intended for rheumatologists and trainees in the rheumatic diseases, as well as orthopedists, internists and other physicians with a special interest in rheumatology.  Individuals interested in keeping up with the “cutting edge,” and in interacting with experts in the field, will find in NYU Seminar in Advanced Rheumatology a vibrant and exciting learning opportunity.

Course Description

The annual NYU Seminar in Advanced Rheumatology is a three-day conference that will review and address those areas where recent, solid knowledge in the treatment of rheumatic diseases is available, focusing particularly on the state of the art in rheumatology, at the leading edge between new clinical knowledge and its translation into practice.  Rheumatology is a fast-moving field in which new discoveries are continually being made, and new treatment modalities developed.  Because the basic and clinical scientific underpinnings of rheumatologic practice frequently and directly come to impact upon therapy, this course will also explore those areas of new science that are likely to prove important to the near-future management of patients with rheumatic disease.  Lectures and Year-In-Review updates will provide participants with the latest information in arthritis, lupus and other rheumatologic conditions; panel discussions and optional Meet-the-Professor sessions will allow participants to raise questions and participate in dialog with the course instructors and clinical experts.

Statement of Need

There are new approaches to the treatment of rheumatoid arthritis, psoriasis and psoriatic arthritis, including newly-available biologic therapies and small-molecule signal transduction inhibitors, as well as the potential for directly managing bone erosion.   Clinicians need to be able to incorporate these new approaches into treatment paradigms, considering both safety and efficacy.  Lupus management remains a core performance area in which rheumatologists require updating. A number of recent research results have clinical implications that are being gradually translated into care. Clinicians need to be aware of newer approaches to the treatment of lupus, including the central role of hydroxychloroquine, the expanding use of mycophenolate mofetil, the recent introduction of belimumab and the potential for new agents in the near future.  Physicians must also be prepared to incorporate new thinking in regards to pathophysiology, genetics and the role of cytokines, as well as to be aware of the co-morbid conditions of SLE, including   cardiac and neurologic disease, and their best management. The role of anti-phospholipid antibodies in tissue injury is another important target of lupus therapy.  Scleroderma is a very difficult disease to modulate, but management of individual aspects of the disease is gradually improving. Therapies for pulmonary hypertension are now in common use, and anti-fibrotic agents for scleroderma are in clinical trials. In addition, the basic biology of the disease is increasingly understood. Clinicians should be aware of the newest insights into the biology of scleroderma, and how these can be applied to improve management of the disease.  Primary vasculitis of the central nervous system is very rare, but it is both life threatening and potentially treatable.  Accordingly, rheumatologists need to be able to recognize, diagnose and treat this entity in order to avoid catastrophic fatality.

Educational Objectives

After participating in this activity, clinicians should be able to:

  • Recognize the clinical benefits, and manage risks of protein based biologic therapies for treatment of rheumatoid arthritis, psoriasis and psoriatic arthritis
  • Develop strategies to determine when to introduce small-molecule signal transduction inhibitors into treatment
  • Recognize the presence of co-morbidities associated with rheumatic diseases and account for these in treatment
  • Evaluate new and future treatment approaches for lupus management
  • Consider the roles of specific immune cells, genetics and cytokines  in the pathogenesis of lupus, and the potential to exploit these factors as therapeutic targets
  • Describe the state of the art regarding mechanisms of vascular disease, fibrosis and organ system dysfunction in scleroderma and inflammatory vasculitis, and to discuss the current treatments for vascular, kidney and pulmonary disease
  • Recognize the signs and symptoms of primary vasculitis of the CNS, and develop strategies to both diagnose and initiate treatment.

Accreditation Statement

The NYU Post-Graduate Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The NYU Post-Graduate Medical School designates this live activity for a maximum of 21.00 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Plenary Sessions

3/17: 6.75 AMA PRA Category 1 Credits™
3/18: 6.75 AMA PRA Category 1 Credits™
3/19: 3.50 AMA PRA Category 1 Credits™

AM Workshops

3/17: 1.00 AMA PRA Category 1 Credits™
3/18: 1.00 AMA PRA Category 1 Credits™

Meet the Professor Luncheon Workshops

3/17: 1.00 AMA PRA Category 1 Credits™
3/18: 1.00 AMA PRA Category 1 Credits™

Refund Policy

In order to request a refund, you must email maria.mercado@nyumc.org no later than 14 days prior to the first day of the course. An administrative fee of $75 will be deducted from your refund. Cancellations or no-shows after this date are not eligible for a refund. 

Course Cancellation Policy
If a course is cancelled due to inclement weather, insufficient enrollment, or any other reason, NYU PGMS will refund registration fees in full. NYU PGMS will provide at least two weeks' advance notice if cancelling due to insufficient enrollment and as soon as possible in all other circumstances. NYU PGMS is not responsible for any airfare, hotel, or other non-cancellable costs incurred by the registrant.